Factor 8 Ehl denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Extended Half-Life Factor VIII as Non-Formulary

UnitedHealthcare's pharmacy formulary designates specific Factor VIII products as preferred or non-preferred. Extended half-life (EHL) Factor VIII products — while FDA-approved and clinically important for many patients with Hemophilia A — may be placed on a non-preferred or specialty tier, or may require a formulary exception, particularly if UHC has negotiated preferred access to a different EHL or standard-acting product. The non-formulary denial issues automatically when a claim for a non-preferred product is submitted without a corresponding formulary exception approval.

## Why This Denial Is Appealable

Formulary exclusion or non-preferred placement does not mean the treatment is inappropriate — it reflects a coverage tier decision, often driven by contracting. UHC's formulary exception process specifically allows patients and prescribers to request coverage of a non-preferred drug when a preferred alternative is clinically inappropriate, has been tried and failed, or when specific clinical circumstances require the non-preferred product. EHL Factor VIII products have distinct pharmacokinetic properties, and a hematologist can document why a specific product is necessary for a specific patient.

## Federal Appeal Rights

• ERISA §503 (employer plans): Full-and-fair internal review; external review after exhaustion.
• ACA §2719 (non-grandfathered plans): External IRO review. Request within approximately four months of the final internal denial — confirm the exact deadline on your denial letter.
• Expedited option: Available if health is at serious risk from delay.

## Appeal Process and Timeline

1. Submit a formulary exception request through UHC's standard exception pathway — often faster than a formal appeal and can be initiated simultaneously. 2. If the exception is denied, file a Level 1 internal appeal within the deadline on the denial. 3. Escalate to Level 2 internal or external IRO review if needed.

## Documentation to Gather

• Preferred alternative tried or contraindicated: Documentation that any UHC-preferred Factor VIII product was tried and was inadequate, or a prescriber attestation that it is clinically inappropriate for this patient.
• Specific clinical rationale for the requested EHL product: A letter from the hematologist explaining the unique pharmacokinetic or clinical characteristics that make this particular EHL product necessary — not just any Factor VIII product.
• Diagnosis and severity documentation: Confirmed Hemophilia A; Factor VIII activity level; bleeding history; target-joint status.
• FDA approval confirmation: Prescribing label confirming the requested product is FDA-approved for Hemophilia A.
• WFH/MASAC guideline support: Reference to guidelines supporting use of EHL products in this patient population.

## Criteria-Mapping Structure

Obtain UHC's formulary exception criteria and map each:

| Exception Criterion | Supporting Evidence | |---|---| | Preferred alternative tried and failed | Treatment history records | | Preferred alternative contraindicated or inappropriate | Prescriber attestation | | Specific medical need for requested EHL product | Prescriber clinical rationale letter | | FDA-approved indication | Prescribing label | | Specialty prescriber | Hematologist credentials |

Formulary exception requests accompanied by a well-reasoned hematologist letter resolve at the first level more often than they proceed to external review.